Report : North America Respiratory Inhalers Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product Type [Nebulizers, Metered Dose Inhalers (MDI), and Dry Powder Inhalers], Technology (Manually Operated Inhalers and Digitally Operated Inhalers), and Disease Indication (Asthma, COPD, Pulmonary Arterial Hypertension, and Others)
At 5.9% CAGR, the North America Respiratory Inhalers Market is speculated to be worth US$ 17,991.07 million by 2028, says The Business Market Insights
According to the Business Market Insights’ research, the North America respiratory inhalers market was valued at US$ 12,747.47 million in 2022 and is expected to reach US$ 17,991.07 million by 2028, registering a CAGR of 5.9% from 2022 to 2028. Rising cases of respiratory disorders and growing adoption of generic inhalers are the critical factors attributed to the North America respiratory inhalers market expansion.
The prevalence of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other respiratory diseases is increasing across the region. In addition, one of the major causes of respiratory diseases such as COPD and asthma is the rise in air pollution. The Organization for Economic Co-operation and Development (OECD) estimates that global emissions of greenhouse gases are likely to increase by ~50% by 2050, mainly due to a 70% increase in CO2 emissions. In addition, it is estimated that the atmospheric concentration of greenhouse gases could reach 685 parts per million (ppm) CO2 equivalent by 2050, which would cause average temperatures to rise 3–6ºC above pre-industrial levels. In addition, the beneficial effects on patients through combination therapy for asthma have increased, which has increased the demand for respiratory inhalers such as dry powder inhalers and soft-mist inhalers, as they are one of the best ways to administer combination drugs. Hence, the increasing prevalence of respiratory diseases among the growing population is one of the factors driving the growth of the North America respiratory inhalers market.
On the contrary, lack of early diagnosis and high cost of inhalers hurdles the growth of North America respiratory inhalers market.
Based on product type, the North America respiratory inhalers market is segmented into nebulizers, metered dose inhalers (MDI), and dry powder inhalers. The dry powder inhalers segment held 42.8% market share in 2022, amassing US$ 5,453.45 million. It is projected to garner US$ 7,567.73 million by 2028 to expand at 5.6% CAGR during 2022–2028.
Based on technology, the North America respiratory inhalers market is bifurcated into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held 71.6% market share in 2022, amassing US$ 9,131.91 million. It is projected to garner US$ 13,106.28 million by 2028 to expand at 6.2% CAGR during 2022–2028.
Based on disease indication, the North America respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. The asthma segment held 35.1% market share in 2022, amassing US$ 4,470.66 million. It is projected to garner US$ 6,544.28 million by 2028 to expand at 6.6% CAGR during 2022–2028.
Based on country, the North America respiratory inhalers market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 70.2% market share in 2022. It was assessed at US$ 8,944.90 million in 2022 and is likely to hit US$ 12,962.56 million by 2028, exhibiting a CAGR of 6.4% during the forecast period.
Key players dominating the North America respiratory inhalers market are AstraZeneca Plc; Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH; Cipla Ltd; GSK Plc; Koninklijke Philips NV; OMRON Corp; OPKO Health, Inc; PARI Respiratory Equipment, Inc.; and Teva Pharmaceutical Industries Ltd among others.
- In Feb 2022, AstraZeneca partnership with Honeywell to develop next-generation respiratory inhalers. AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.
- In Feb 2022, Beximco Pharmaceuticals Launched Fixonase Nasal Spray. Fixonase Nasal Spray is the preparation of Fluticasone Furoate (27.5 g) indicated to treat symptoms of seasonal and perennial allergic rhinitis in patients above 2 years of age including stuffy, runny, or itchy nose, sneezing and watery, itchy, or red eyes.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com